�With some 20,000 UK children with Type 1 diabetes(i) around to go the
unexampled school class, new steering from the National Institute for Health and
Clinical Excellence (NICE) looks set to overturn the way children
manage
their diabetes, granting more than freedom and control for their condition, by
greater access to insulin pump therapy. The new recommendations finally
acknowledge key inquiry(ii) supported by Roche, that shows the positivist
impact of pumps on quality of life for sufferers and their families.
Roche, a world loss leader in diabetes care and management services, has
been
working close with diabetes healthcare specialists to arouse awareness of
pump therapy and encourage and support new users. Roche welcomes the new
guidelines that recommend greater access to insulin pump therapy to manage
Type 1 diabetes, particularly amongst children and young people, with
pumps
replacing traditional insulin injections which get been shown to
break
the school day(ternary).
Dr Katharine Barnard PhD, School of Psychology at the University of
Southampton, one of the UK's leading regime into calibre of life
issues
surrounding insulin pumps in Type 1 diabetes, who has worked with Roche
says:
"There are significant psychosocial benefits associated with insulin pump
therapy, particularly improved quality of life. The new NICE guidelines
should facilitate greater access to this therapy, which volition only be good
news for patients and their families. For children it should have got a
positive
impact on both their school and home life."
Benefits of replacing injections with insulin pump therapy include
fewer
hypoglycaemic episodes, the chance to enter in sports without
having to plan ahead and the alternative to eat on a wider variety of food as the
pump can be easily familiarised to supply the correct amount of insulin each
moment
of the day.
Britain is lagging behind other major countries in terms of diabetes
management with less than 1% of Type 1 cases using an insulin pump in the
UK,
compared to many other countries such as US and Germany where 15-20% use a
pump(iv). With a five-spot fold step-up in the number of under fives diagnosed
over the past tense 20 age(v), and 1 child in 1,000(vi) affected, access to
insulin pump therapy is essential for children to get the opportunity to
live as close to a normal a life as possible and feel less 'controlled' by
their diabetes as Dr Barnard's adolescent study amongst pump users found.
Dr Barnard continued: "The new guidance should hopefully receptive up access
to children and their families and pumps are then provided according to
need,
pick and suitability."
Insulin pumps are non suitable for everyone and they need thorough
explanation and training. People lav find prohibited more by visiting
hTTP://www.accu-chek.co.uk where they can experience the Accu-Chek Spirit
on-line simulator, the most advanced insulin pump from Roche which tight
mimics the pancreas by delivering insulin every threesome minutes(vii).
About Roche
Headquartered in Basel, Switzerland, Roche is one of the world's
leading
research-focused healthcare groups in the fields of pharmaceuticals and
diagnostics. As the world's biggest biotech company and an trailblazer of
products and services for the early spying, prevention, diagnosing and
treatment of diseases, the Group contributes on a all-inclusive range of fronts to
improving people's health and quality of life. Roche is the world loss leader
in
in vitro diagnostics and drugs for cancer and transplantation, and is a
market leader in virology. It is also active in other major alterative
areas
such as autoimmune diseases, seditious and metabolic disorders and
diseases of the central nervous system. In 2007 sales by the
Pharmaceuticals
Division totalled 36.8 billion Swiss francs, and sales by the Diagnostics
Division totalled 9.3 billion Swiss francs. Roche Diabetes Care posted
2007
sales of 3.2 billion Swiss francs. Roche has R&D agreements and strategic
alliances with legion partners, including majority ownership interests
in
Genentech and Chugai, and invested over 8 one million million Swiss francs in R&D in
2007. Worldwide, the Group employs about 80,000 hoi polloi. Additional
info is uncommitted on the Internet at http://www.roche.com.
About Roche Diabetes Care
Roche Diabetes Care is a pioneer in the development of blood glucose
monitoring systems and a global leader for diabetes management systems and
services. For more than 30 years, the Accu-Chek brand has been committed
to
enable citizenry with diabetes to live life as normal and active as possible
as
well as to help healthcare professionals manage their patients' condition
in
an optimal way. Today, the Accu-Chek portfolio offers masses with diabetes
and healthcare professionals innovative products and services and
comprehensive solutions for convenient, efficient and effective diabetes
management spanning from blood glucose monitoring through information
management to insulin manner of speaking. The Accu-Chek brand encompasses blood
glucose
meters, insulin delivery systems, lancing devices and data management
systems.
http://www.accu-chek.com
All trademarks used or mentioned in this passing are de jure protected by
law.
(i) Juvenile Diabetes Research Foundation
(ii) Barnard, K.D., Speight. J. & Skinner, T.C. Impact of insulin pump
therapy on quality of life of children/adolescents with Type 1 diabetes
and
their parents: an overview study. Practical Diabetes International,
October
2008.
(iii) Barnard, K.D., discipline as in a higher place
(iv) Diabetes UK, Insulin Pump Services - Report of the Insulin Pumps
Working Group, March 2007
(v) University of Bristol, March 2007 (PJ Bingley, Department of Clinical
Science)
(vi) University of Bristol, March 2007 (PJ Bingley, Department of
Clinical Science)
(vii) Encyclopedia of Endocrine Diseases, Volume 3, p48. Insulin
Secretion Physiology. Elsevier Inc. 2004.
http://www.accu-chek.com
More info
